On the fly News and insights, exclusive to thefly.com

MYOV

Myovant Sciences

$11.86

5.84 (97.01%)

14:11
11/19/19
11/19
14:11
11/19/19
14:11

JMP boosts Myovant price target to $34 after 'compelling' prostate cancer data

JMP Securities analyst Jason Butler raised his price target for Myovant Sciences to $34 from $25 saying the company's "compelling" Phase 3 results in prostate cancer "clearly demonstrate" the clinical value of relugolix. The stock in afternoon trading is up 99%, or $6.14, to $12.20. The analyst views today's data as the best case outcome for relugolix and he increased his probability of approval in prostate cancer to 90% and peak penetration from 6% to 15%. The results support that relugolix is "clearly superior" to GnRH agonists including leuprolide, and also de-risk regulatory approvals in the U.S. and Europe, Butler tells investors in a research note. He reiterates an Outperform rating on shares of Myovant Sciences.

  • 19

    Nov

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.